Ex vivo–pulsed dendritic cells prime neoantigen-specific T cells; vaccine-activated CD4+ (and supportive CD8+) T cells recognize the neoantigen on HLA class II–positive tumor cells and kill via perforin/granzyme and/or Fas–FasL–mediated apoptosis.